CD8A and non-small cell lung carcinoma: Moreover, Stanczak et al. (81) described the Sia-SAMP:Siglec-9 as an inhibitory pathway in NSCLC, where high frequencies of Siglec9+CD8+ TILs inversely correlate with survival (81).